The stock of Heat Biologics Inc (NASDAQ:HTBX) is a huge mover today! About 9.08 million shares traded hands or 790.20% up from the average. Heat Biologics Inc (NASDAQ:HTBX) has risen 180.88% since April 22, 2016 and is uptrending. It has outperformed by 175.47% the S&P500.
The move comes after 9 months positive chart setup for the $79.01M company. It was reported on Nov, 25 by Barchart.com. We have $2.84 PT which if reached, will make NASDAQ:HTBX worth $5.53M more.
Analysts await Heat Biologics Inc (NASDAQ:HTBX) to report earnings on February, 16. They expect $-0.09 earnings per share, up 88.46% or $0.69 from last year’s $-0.78 per share. After $-0.08 actual earnings per share reported by Heat Biologics Inc for the previous quarter, Wall Street now forecasts 12.50% negative EPS growth.
Heat Biologics Inc (NASDAQ:HTBX) Ratings Coverage
Out of 4 analysts covering Heat Biologics (NASDAQ:HTBX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Heat Biologics has been the topic of 5 analyst reports since September 1, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald maintained Heat Biologics Inc (NASDAQ:HTBX) rating on Tuesday, September 1. Cantor Fitzgerald has “Buy” rating and $18 price target. The stock of Heat Biologics Inc (NASDAQ:HTBX) earned “Buy” rating by H.C. Wainwright on Thursday, September 3. The stock of Heat Biologics Inc (NASDAQ:HTBX) has “Buy” rating given on Monday, June 20 by Roth Capital. The firm earned “Buy” rating on Friday, January 8 by Noble Financial. The stock has “Speculative Buy” rating given by Cantor Fitzgerald on Thursday, February 4.
According to Zacks Investment Research, “Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company’s products under development include HS-110 for the treatment of non-small cell lung cancer, HS-410 for the bladder cancer treatment, HS-310 to treat ovarian cancer and HS-510 for treating triple negative breast cancer. Heat Biologics, Inc. is based in Chapel Hill, North Carolina.”
Insitutional Activity: The institutional sentiment increased to 2.67 in 2016 Q2. Its up 2.37, from 0.3 in 2016Q1. The ratio is positive, as 6 funds sold all Heat Biologics Inc shares owned while 4 reduced positions. 1 funds bought stakes while 2 increased positions. They now own 1.66 million shares or 39.04% less from 2.72 million shares in 2016Q1.
Franklin Street Advsrs Nc accumulated 0.01% or 70,500 shares. Bancorporation Of America De last reported 5,000 shares in the company. Morgan Stanley reported 12,168 shares or 0% of all its holdings. Blackrock Limited Liability has 0% invested in the company for 2,991 shares. Vanguard Incorporated last reported 86,527 shares in the company. Moreover, Wells Fargo And Mn has 0% invested in Heat Biologics Inc (NASDAQ:HTBX) for 231 shares. Blackrock Fund has 1,631 shares for 0% of their US portfolio. Renaissance Technologies Limited Com holds 0% of its portfolio in Heat Biologics Inc (NASDAQ:HTBX) for 112,200 shares. Manufacturers Life Comm The last reported 0% of its portfolio in the stock. Goldman Sachs Grp Inc last reported 0% of its portfolio in the stock. Moreover, Royal National Bank & Trust Of Canada has 0% invested in Heat Biologics Inc (NASDAQ:HTBX) for 264 shares. Moreover, Franklin Resources has 0% invested in Heat Biologics Inc (NASDAQ:HTBX) for 1.33M shares. Geode Cap Mngmt Ltd Liability accumulated 22,034 shares or 0% of the stock.
HTBX Company Profile
Heat Biologics, Inc., incorporated on June 10, 2008, is a development-stage firm focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Firm is an immuno-oncology firm developing therapies intended to activate a patient’s immune system to fight cancer. The Company, by using its T cell-stimulating platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), has generated several product candidates for treating certain forms of cancer. The Company’s platform technologies address over two synergistic mechanisms of action, including the activation of CD8+ T cells, or killer T cells, and T cell co-stimulation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.